Non-therapeutic use of hyperbranched dextrins as sedatives

Abstract

The present invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, for use as a soothing agent and in a method for preventing or reducing or eliminating reactions of the skin and / or scalp and / or oral mucosa.

Description

[Technical field]

[0001] The present invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, for use as a soothing agent and in a method for preventing or reducing or reversing skin and oral mucosal reactions. [Background technology]

[0002] The skin and oral mucosa constitute both an anatomical barrier of the organism and an exchange zone between the body and its environment, the effectiveness of which determines the maintenance of a good homeostatic balance. The skin comprises a superficial layer, the epidermis, composed of keratinized epithelial cells, and a deeper layer, the dermis and subcutaneous tissue, each of which has specific properties that allow it to react and adapt to environmental conditions. The oral mucosa has a structure similar to that of the skin, with the difference that it does not have a superficial layer of keratinized epithelial cells, but instead its surface is composed of non-keratinized epithelial cells.

[0003] Cutaneous and oral mucosal reactions can be caused by the environment, e.g., low temperature, UV radiation, friction, food or beverages, as well as by certain products and active ingredients present in cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household compositions. These skin reactions cause discomfort such as heat, tension, tingling, itching and numbness on the skin, scalp and oral mucosa of the user. These skin reactions are more pronounced on sensitive skin and scalp, as well as sensitive mucosa. Cosmetic treatments can reduce these discomforts associated with skin and oral mucosal reactions by providing a soothing effect when the cosmetic product is applied.

[0004] Thus, there is a need to identify soothing compounds that can also prevent, reduce and soothe skin and oral mucosal reactions caused by environmental or cosmetic agents.

[0005] Certain C-glycoside derivatives are known for their soothing properties and are incorporated into cosmetic compositions. Citation may be made of those disclosed in document FR2902998. Summary of the Invention

[0006] The Applicant has demonstrated that a hyperbranched dextrin marketed by Roquette under the name Nutriose® HM 06 relieves the sensation of burning and tightness caused by exposure of the forearm skin to sodium lauryl sulfate (SLS) for 20 hours.

[0007] The present invention relates to the use of hyperbranched dextrins as sedatives.

[0008] The present invention further relates to the use of hyper-branched dextrins for preventing or reducing or eliminating skin and / or oral mucosal reactions.

[0009] The present invention further relates to a method for the non-therapeutic care of the skin and / or scalp and / or oral mucosa comprising the application of hyperbranched dextrin to the skin and / or scalp and / or oral mucosa.

[0010] The present invention further relates to a cosmetic composition comprising a hyperbranched dextrin in a cosmetically acceptable medium.

[0011] These compositions are suitable for all skin types, in particular for sensitive skin and / or scalp and sensitive oral mucosa. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is an illustration of hyperbranched dextrin according to the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hyperbranched dextrin According to a first embodiment, the dextrins useful for non-therapeutic uses for the purposes of the present application are hyperbranched dextrins.

[0014] By "dextrins" the Applicant means glucose polymers obtained from granular starch, usually by the action of acids in a generally dry environment, i.e. by thermal conversion to granules in the form of dry solid particles containing residual moisture imposed by the physical equilibrium conditions at a given temperature and pressure. Thus, maltodextrins and calcined dextrins, when they are modified to branch, are included in the general family of dextrins useful in the present invention.

[0015] In the context of the present invention, "dextrin" further means, according to the applicant, glucose polymers derived from the acid or enzymatic liquefaction or hydrolysis of starch, commonly called "maltodextrins", "starch hydrolysates" or "glucose syrups", which polymers have been further chemically or enzymatically modified, in particular by branching enzymes, to have glucosidic bonds between the anhydroglucose molecules whose nature is significantly different from that of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and pyrodextrins are classified into the general family of dextrins useful in the present invention, since they differ in carbohydrate linkages from the starches from which they are derived, by including "atypical" bonds.

[0016] According to the Applicant, "hyperbranched dextrins" means "dextrins" having glucosidic bonds between anhydroglucose molecules that differ significantly in nature and amount from those that naturally constitute the starch from which it is derived. They include the naturally occurring glucosidic bonds between anhydroglucose molecules, 1-6 bonds, but in greater amounts, and the glucosidic bonds that do not naturally occur in starches, known as "atypical", 1-3 bonds and 1-2 bonds. Thus, hyperbranched dextrins are dextrins that have a high proportion of branched glucosidic bonds relative to the total glucosidic bonds present in the abovementioned dextrins. The term "hyperbranched" can also be interchanged with "highly branched".

[0017] By "high percentage" is meant a percentage of branched glucosidic bonds of 5% or more, preferably 10% or more, more preferably 20% or more, more preferably 30% or more, more preferably 40% or more, more preferably 50% or more of the total of branched and linear glucosidic bonds. Glucosidic branching bonds are bonds that produce non-linear chains in a higher percentage than normal for native starch. The glucosidic bonds that produce non-linear chains are glucosidic 1-6 bonds, 1-3 bonds, and 1-2 bonds, as shown in Figure 1 [Figure 1]. The 1-3 and 1-2 bonds are atypical glucosidic bonds. The normal values ​​for these bonds in native starch are about 5% for 1-6 bonds and about 0% for 1-2 and 1-3 bonds. The remainder is made up of 1-4 glucosidic bonds, i.e. about 95%. The 1-4 bonds are bonds that form linear bonds.

[0018] For 1-6 glucosidic bonds, the characteristic values ​​of the hyperbranched dextrins useful in the present invention are greater than 5% for the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably greater than 10% for the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, more preferably greater than 12% for the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and most preferably greater than 15% for the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0019] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 5%, preferably at least 10%, preferably at least 12%, preferably at least 15% 1-6 glucosidic bonds relative to the sum of alpha 1-2, 1-3, 1-4 and 1-6 bonds.

[0020] For 1-2 and 1-3 glycosidic bonds, values ​​greater than 1% based on the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably 5% or more based on the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and more preferably 10% or more based on the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, are useful in the present invention.

[0021] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, and preferably at least 20% 1-2 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0022] According to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, and preferably at least 20% 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0023] For the 1-4 glycosidic bond, values ​​of less than 70%, preferably less than 60%, preferably less than 50%, based on the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and preferably between 42 and 50%, based on the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, are useful in the present invention.

[0024] Thus, according to one embodiment, the hyperbranched dextrin contains at most 70%, preferably at most 50%, 1-4 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0025] Preferably, the hyperbranched, preferably hyperbranched and hydrogenated dextrins useful in the present invention have a 1-6 glucosidic bond content of 5% to 40%, preferably 10% to 30%, more preferably 12% to 22%, and most preferably 15% to 20%, based on the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0026] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched and hydrogenated dextrin, useful in the present invention is - 5% to 40%, preferably 10% to 30%, more preferably 12% to 22%, and most preferably 15% to 20% of 1-6 glycosidic bonds relative to the total of 1-2, 1-3, 1-4 and 1-6 bonds; - 42-50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-20% of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; -Having 1-2 glycosidic bonds in an amount of 1-2 to 20% based on the total amount of 1-2, 1-3, 1-4 and 1-6 bonds.

[0027] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched and hydrogenated dextrin, useful in the present invention is - at least 5%, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 70% or less, preferably 60% or less, and most preferably 50% or less, of 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0028] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched and hydrogenated dextrin, useful in the present invention is - 5% to 40%, preferably 10% to 30%, more preferably 12% to 22%, and most preferably 15% to 20% of 1-6 glycosidic bonds relative to the total of 1-2, 1-3, 1-4 and 1-6 bonds; - 42 to 70%, preferably 42 to 60%, of 1-4 glycosidic bonds relative to the total of 1-2, 1-3, 1-4 and 1-6 bonds; -1-3 glucosidic bonds are 1 to 20%, preferably 1 to 10%, more preferably 5 to 15%, and most preferably 5 to 10% of the total of -1-2, 1-3, 1-4 and 1-6 bonds, and -1-2 glucosidic bonds are 1 to 20%, preferably 1 to 10%, more preferably 5 to 15%, and most preferably 5 to 10% of the total of -1-2, 1-3, 1-4 and 1-6 bonds.

[0029] Apart from the use of the well-known thermal conversion processes applied to granular starch to prepare dextrins, i.e. by using acids on granular starch, typically at high temperatures in a dry environment, these atypical contents of branched bonds in starch can also be obtained by the action of so-called "branching" or "rebranching" enzymes on liquefied starches, such as maltodextrins, starch hydrolysates or glucose syrups, optionally previously or subsequently hydrogenated.

[0030] These atypical bond contents can therefore be obtained both by the action of "branching" or "rebranching" enzymes on liquefied starch and / or by the action of acids on granular or liquefied starch, typically in a drying medium at high temperatures.

[0031] The content of 1-2, 1-3, 1-4 and 1-6 glucosidic bonds can be determined using the conventional methylation technique described in HAKOMORI, S., 1964, J. Biochem., 55, 205. "A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide". This method allows the chemical characterization of the glucosidic bonds by distinguishing between free OH groups and the bonded group. It is a destructive method that includes the steps of methylation, hydrolysis, reduction with NaBD4, acetylation and analysis by mass spectrometry.

[0032] According to one embodiment, the above-mentioned hyper-branched dextrin has a number average molecular weight Mn of 10,000 g / mol or less, preferably 4,500 g / mol or less, more preferably 1,000 to 3,500 g / mol, even more preferably 1,500 to 3,500 g / mol, and most preferably 1,800 to 3,200 g / mol.

[0033] According to one embodiment, the above-mentioned hyperbranched dextrins have a polymolecular index, i.e. the ratio of the weight average molar mass to the number average molar mass (denoted IP), less than or equal to 15, preferably less than or equal to 10, more preferably less than or equal to 5, and most preferably less than or equal to 3.

[0034] The Mn, Mw and IP values ​​are determined by steric exclusion chromatography, based on the size-selective retention of solute molecules by permeation or non-permeation into the pores of the stationary phase. The size exclusion chromatography columns used were PSS SUPREMA 100 and PSS SUPREMA 1000, connected in series and coupled to a light scattering detector.

[0035] According to one embodiment, the above-mentioned hyper-branched dextrin has a reducing sugar content of less than or equal to 20%, preferably less than or equal to 15%, more preferably less than or equal to 10%, even more preferably less than or equal to 6% and most preferably less than or equal to 3% relative to the total mass of the hyper-branched dextrin. The reducing sugar content, expressed as glucose by weight relative to the dry weight of the product analyzed, is determined by the Bertrand method.

[0036] According to one embodiment, the hyperbranched dextrins useful in the present invention have a relatively high content of residual 1-4 glucosidic bonds. This content of 1-4 glucosidic bonds is between 42 and 50% relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, and the content of 1-6 glucosidic bonds is between 12 and 22% relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful in the present invention have a 1-4 / 1-6 glucosidic bond ratio of between 1.9 and 4.2, in particular between 2.3 and 3.5.

[0037] According to one embodiment, the hyperbranched dextrins useful for the invention have a 1-3 glucosidic bond content of 1 to 10% relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, in combination with a 1-4 glucosidic bond content of 42 to 50% relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful for the invention have a 1-4 / 1-3 glucosidic bond ratio of 0.02 to 0.24, in particular 0.1 to 0.2. According to one embodiment, the hyperbranched dextrins useful for the invention have a content of 1-2 glucosidic bonds of 1 to 10% in combination with a content of 1-4 glucosidic bonds of 42 to 50%. Preferably, the hyperbranched dextrins useful for the invention have a 1-4 / 1-2 glucosidic bond ratio of 0.02 to 0.24, in particular 0.1 to 0.2.

[0038] According to one embodiment, the hyperbranched dextrins useful for the present invention are - 5% to 40% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; a reducing sugar content of less than 20% relative to the total mass of the hyperbranched dextrin and a polymolecular index of less than or equal to -15; and a number average molecular weight Mn of 4,500 g / mol or less.

[0039] According to one embodiment, the hyperbranched dextrins useful for the present invention are - 10% to 30% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42-70% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; a reducing sugar content of less than 10% based on the total mass of hyperbranched dextrin; A polymolecular index of less than -10; and a number average molecular weight Mn of -1,000 to 3,500 g / mol.

[0040] According to one embodiment, the hyperbranched dextrins useful for the present invention are - 12% to 22% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42-50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-20% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-2 glycosidic bonds, based on the total of 1-2, 1-3, 1-4 and 1-6 bonds, from 1 to 20%; a reducing sugar content of less than 6% based on the total mass of hyperbranched dextrin; A polymolecular index of -5 or less; and a number average molecular weight Mn of -1,500 to 3,000 g / mol.

[0041] Hyperbranched dextrins useful in the present invention are commercially available, for example, from Roquette®'s "Nutriose® FM 06", "Nutriose® FM 10" and "Nutriose® FM15S" products, or from Tate & Lyle's "Promitor® Soluble fiber" product line.

[0042] Other commercially available products available under the name "STA-LITE® Polydextrose" from Tate & Lyle or "Oliggo-fiber®" from Cargill are hyperbranched polysaccharides or oligosaccharides which, either as such or after possible hydrogenation, are believed to have soothing properties like the hyperbranched dextrins disclosed in the present application.

[0043] Hyperbranched and Hydrogenated Dextrins According to a second embodiment, the dextrins useful for non-therapeutic uses for the purposes of the present application are hyperbranched and hydrogenated dextrins. Such dextrins can be obtained by subjecting hyperbranched dextrins for the purposes of the present application to hydrogenation or by applying the "branching" or "rebranching" methods to previously hydrogenated dextrins. Hydrogenation can be achieved, for example, by exposing an aqueous solution of hyperbranched dextrin to hydrogen gas in the presence of a catalyst such as Raney nickel.

[0044] An additional feature can be added to the above-described embodiment for hyper-branched dextrins, namely a reducing sugar content of less than or equal to 5% by weight, preferably less than or equal to 3% by weight, more preferably less than or equal to 2% by weight, more preferably less than or equal to 1% by weight, more preferably less than or equal to 0.5% by weight, and most preferably less than or equal to 0.15% by weight.

[0045] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention are - 5% to 40% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; a reducing sugar content of less than 4% relative to the total mass of hyperbranched dextrin; A polymolecularity index of less than or equal to -15; and a number average molecular weight Mn of 4,500 g / mol or less.

[0046] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention are - 10% to 30% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42-70% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; a reducing sugar content of less than 3% based on the total mass of hyperbranched dextrin; A polymolecular index of less than -10; and a number average molecular weight Mn of -1,000 to 3,500 g / mol.

[0047] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention have between 12% and 22% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42-50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-20% of 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-2 glycosidic bonds, based on the total of 1-2, 1-3, 1-4 and 1-6 bonds, from 1 to 20%; a reducing sugar content of less than 2% based on the total mass of hyperbranched dextrin; A polymolecular index of -5 or less; and a number average molecular weight Mn of -1,500 to 3,000 g / mol.

[0048] Hyperbranched and hydrogenated dextrins useful in the present invention are commercially available, such as "Nutriose® HM 06" from Roquette.

[0049] Painkillers An object of the present invention is the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as analgesics.

[0050] Sedatives are agents that prevent the onset of skin and / or oral mucosal reactions, reduce the intensity of these reactions, or eliminate them.

[0051] Thus, according to one embodiment, an object of the present invention is the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as soothing agents for skin and / or oral mucosal reactions.

[0052] "Cutaneous" refers to the skin, i.e., the outer covering of the human body and of vertebrate bodies, including the human scalp. Cutaneous reactions cause discomfort to the skin and scalp of the user. Cutaneous reactions include a feeling of warmth, tightness, tingling, numbness, and itching. These reactions are non-pathological skin reactions.

[0053] Thus, according to one embodiment, an object of the present invention is the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, as soothing agents for skin reactions of the skin and / or scalp.

[0054] According to one embodiment, the skin reaction is selected from a warming sensation, tightness, tingling, numbness and itching.

[0055] "Oral mucosa" refers to the lips, tongue, tongue bed, gums, inner surfaces of the cheeks and lips, palate and soft palate in humans and vertebrate animals.

[0056] Oral mucosal reactions cause discomfort on the lips, gums, inside of the cheeks or roof of the mouth. Oral mucosal reactions include a warming sensation, a burning sensation, tightness, tingling, numbness and itching. According to one embodiment, the oral mucosal reaction is selected from a burning sensation, a tingling sensation or numbness.

[0057] These skin reactions are increased in individuals with sensitive skin or scalp. However, unlike allergic skin, this reactivity is not the result of an immunological process. Sensitive skin is defined by a specific reactivity. This skin reactivity is traditionally translated into the expression of previously defined symptoms of discomfort (e.g., burning, tightness, tingling, numbness, and itching). These skin reactions may be a reaction to contact with a triggering element. These skin reactions can occur in all skin types, but are more frequent in skin in a state of hypersensitivity, indicated by the term "sensitive skin", and correspond to a condition of skin with increased sensitivity to external stimuli, i.e., a sensitivity higher than the population average or higher than the individual's normal.

[0058] "Sensitive scalp" refers to a scalp in which itching and / or stinging and / or burning sensations are essentially caused by topical factors such as friction, soap, detergents, hard water with high lime content, shampoos or lotions. These sensations may also be caused by factors such as the environment, emotions and / or food. Scalp erythema, hyperseborrhea and dandruff are often associated with the above symptoms.

[0059] According to one embodiment, the skin reaction is a skin reaction of sensitive skin and scalp.

[0060] The term "sensitive oral mucosa" refers to an oral mucosa that exhibits an exacerbated sensitivity compared to the average sensitivity of the population or compared to the normal sensitivity of an individual. This sensitivity may be manifested by contact with surfactants such as sodium lauryl sulfate, alcohols such as ethanol, whitening agents such as peroxides, or active ingredients or essential oils used in mouthwash, gel or toothpaste compositions.

[0061] According to one embodiment, the skin and oral mucosal responses are induced by endogenous or exogenous stress.

[0062] These skin reactions can be triggered by exogenous stresses such as: - Chemical substances or formulation ingredients. -Mechanical aggressions selected from rubbing, shaving, cutting, micro-cutting, depilation, polishing, scrubbing, frequent washing, hard water with high limestone concentration. Environmental factors, such as pollution, exposure to UV rays and sunlight. - Thermal aggression selected from excessive exposure to the sun and exposure to hot or cold sources. - Foods and beverages that are abrasive or chemically aggressive, e.g. to the oral mucosa.

[0063] Intrinsic factors such as hormonal secretions, age, stress, sweating, etc. can also induce skin or oral mucosal reactions.

[0064] Preventing, reducing or eliminating skin and / or oral mucosal reactions The present invention further relates to the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, to prevent or reduce or eliminate skin and / or oral mucosal reactions.

[0065] According to one embodiment, the skin reaction is selected from a warming sensation, tightness, tingling, numbness and itching.

[0066] According to one embodiment, the oral mucosal reaction is selected from a burning sensation, a warm sensation, tightness, tingling, numbness and itching.

[0067] Prevention of a skin or oral mucosal reaction means preventing the onset of one or more skin or oral mucosal reactions, delaying the onset of one or more skin or oral mucosal reactions, and preventing the worsening of one or more skin or oral mucosal reactions.

[0068] The reduction of skin or oral mucosa reaction means the reduction of one or more skin or oral mucosa reactions.For example, the reduction of skin reaction means the reduction of the intensity of warmth, tension, tingling, numbness and itching.For example, the reduction of oral mucosa reaction means the reduction of the intensity of warmth, burning, tension, tingling, numbness, itching, and the reduction of the intensity of dry mouth, nausea and nausea, especially when brushing teeth.

[0069] Absence of skin or oral mucosal reactions means the absence of one or more skin or oral mucosal reactions.

[0070] According to one embodiment, the skin and scalp are sensitive skin and scalp.

[0071] According to one embodiment, the skin and oral mucosal reactions are induced by endogenous or exogenous stress as defined above.

[0072] beauty method The present invention further relates to a method for the non-therapeutic care of the skin and / or scalp and / or oral mucosa comprising the application of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, to the skin and / or scalp and / or oral mucosa.

[0073] The hyperbranched dextrins can be applied in the form of cosmetic compositions which contain them.

[0074] According to one embodiment, the hyperbranched dextrins or cosmetic compositions comprising them are applied to the area to be soothed of an individual exhibiting one or more skin or oral mucosal reactions, optionally left in contact for minutes or hours, and optionally washed off. As a result, this method can be carried out during or after the stimulation and can be repeated or renewed as frequently as necessary, for periods ranging from days to months or even years.

[0075] Thus, according to one embodiment, the method comprises applying hyperbranched dextrins or cosmetic compositions comprising them to the skin and / or scalp and / or oral mucosa exhibiting one or more skin or oral mucosa reactions.

[0076] According to one embodiment, the method comprises the additional step of leaving the compound in contact with the skin and / or scalp and / or oral mucosa.

[0077] According to one embodiment, the method comprises an additional flushing step.

[0078] Alternatively, the hydrogenated hyperbranched dextrins or cosmetic compositions containing them may be applied before the application of a cosmetic or dermatological treatment.

[0079] According to one embodiment of the present invention, such preventative methods are used in cosmetic or dermatological pretreatments to prevent the onset of one or more skin and / or oral mucosal reactions that may occur during exposure to low temperature, high temperature, sunlight, pollution sources, food, etc., or during the application of a cosmetic or dermatological composition containing one or more irritants, a subsequent cosmetic or dermatological treatment, such as coloring, bleaching, perming, straightening, peeling, anti-rosacea treatment, etc.

[0080] The present invention therefore also relates to a non-therapeutic skin and / or scalp and / or oral mucosa care method, comprising at least two steps: a first pre-treatment step consisting of the application of hyperbranched dextrins or cosmetic compositions comprising them to the skin and / or scalp and / or oral mucosa, intended to prevent the occurrence of one or more skin and / or oral mucosa reactions, and a second step subsequent to the first step of applying a cosmetic or dermatological treatment.

[0081] According to one embodiment of the present invention, hyperbranched dextrins or cosmetic compositions containing them can be applied in anticipation of endogenous and / or exogenous stress.

[0082] Endogenous and / or exogenous stress is as defined above.

[0083] Cosmetic composition The hyperbranched dextrin, preferably hydrogenated hyperbranched dextrin, can be incorporated into cosmetic compositions.

[0084] The present invention therefore further relates to a cosmetic composition comprising a hyperbranched dextrin and a cosmetically acceptable medium.

[0085] "Cosmetically acceptable" is understood to mean a medium that does not exhibit harmful side effects, in particular does not cause redness, irritation, burning, tightness or stinging that is unacceptable to the user of the cosmetic product under normal conditions of use. The medium is therefore compatible with the skin, the scalp and the oral mucosa of humans and animals.

[0086] According to one embodiment, the compounds according to the invention may be incorporated into cosmetic compositions containing one or more compounds prone to causing skin irritation.

[0087] According to one embodiment, the hyperbranched dextrins or cosmetic compositions comprising them are applied to non-pathological skin exhibiting one or more non-pathological skin reactions.

[0088] According to one embodiment, the content of hyperbranched dextrins is between 0.1 and 50% by weight, preferably between 0.5 and 20% by weight, more preferably between 1 and 10% by weight and most preferably between 1.5 and 7.5% by weight, and generally between 2 and 5% by weight, relative to the total weight of the composition.

[0089] Form of application The cosmetic compositions according to the invention may be in any of the pharmaceutical forms usually used for topical application, such as aqueous, hydroalcoholic or oily solutions, solutions or dispersions of lotion or serum type, emulsions of liquid or semi-liquid consistency of milk type obtained by dispersing a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of cream or aqueous or anhydrous gel type, anhydrous compositions, solid compositions, microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and / or non-ionic type. For the purposes of the present invention, "topical application" means application to a body surface such as the skin or mucous membranes.

[0090] These compositions are prepared according to the usual methods known to those skilled in the art.

[0091] This composition, when applied to the skin, can be more or less fluid and can have the appearance of a cream, emulsion or microemulsion, ointment, milk, lotion, serum, paste, foam, mask, fluid, balm, oil, gel, ointment, mouthwash, toothpaste, gumpaste.In some cases, it can be applied to the skin in aerosol form.It can also be in solid form, for example in the form of a stick or patch, or in the form of a dry soap or cleansing bar.

[0092] It can be used as a skin care product, especially for leave-on applications such as a day or night cream for the skin of the face and / or body, as a cleanser, as a make-up product, as a deodorant, as a shaving product, as an aftershave product, as an aftersun product, as a sun protection product, as a lip balm for protecting the lips from the cold and / or sun and / or wind, etc., and also as a rinse-off skin care product.

[0093] The compositions according to the invention may further be in the form of scalp and hair care compositions, in particular in pharmaceutical forms for rinse-off applications such as shampoos, hair conditioners, hair masks, serums, foams, balms, creams, sprays, conditioners, detanglers, hair creams, mousses, balms, creams, sprays, conditioners, as well as treatment lotions, dye compositions, colour shampoos, perm compositions, anti-hair loss lotions or gels, anti-parasitic shampoos, conditioners, etc. The compositions according to the invention may further be scalp and hair care compositions, in particular in pharmaceutical leave-on forms.

[0094] Formulation ingredients The cosmetic composition according to the present invention may further comprise a solvent, which is selected based on the various ingredients and the mode of administration.

[0095] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and, optionally, one or more water-miscible organic solvents.

[0096] The term "water-soluble solvent" refers to a compound that is liquid at room temperature and is water-miscible (greater than 50% by weight miscible in water at 25° C. and atmospheric pressure).

[0097] The water-soluble solvents that can be used in the compositions according to the present invention may be volatile.

[0098] Among the water-soluble solvents that can be used in the composition according to the invention, monoalcohols having 1 to 5 carbon atoms, such as ethanol and isopropanol, C 3 ~C 4 Ketones and C 2 ~C 4 Mention may be made of aldehydes and polyols, in particular glycerol or glycerin, sorbitol or isosorbide.

[0099] In addition to the hyperbranched dextrin, the cosmetic composition may also comprise:

[0100] -One or more wetting agents The humectant may be selected from polyols and / or esters of fatty acids and polyethylene glycol.

[0101] "Polyol" is understood to mean any molecule that has in its structure at least two free hydroxy (-OH) groups. These polyols are preferably liquid at room temperature (25°C).

[0102] Typically, the polyol is selected from maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol or glycerin, glucose, sucrose, polydextrose, hydrogenated glucose syrup, dextrin, maltodextrin, glucose syrup, and mixtures thereof.

[0103] Examples include Beaute by Roquette® PO 071 (INCI: Sorbitol), Beaute by Roquette® PO 260 (INCI: Mannitol), Beaute by Roquette® PO 370 (INCI: Xylitol), Beaute by Roquette® PO 455 (INCI: Hydrogenated starch hydrolysate), Beaute by Roquette® PO 500 (INCI: Isosorbide), glycerin (INCI: glycerin) sold by COOPER, propylene glycol (INCI: propylene glycol) sold by COOPER, butylene glycol (INCI: 1,3-BUTANEDIOL), all sold by ROQUETTE.

[0104] Among the esters of fatty acids and polyethylene glycol, a product sold under the name Glucamate SSE-20 (INCI: PEG-20 METHYL GLUCOSE SESQUISTEARATE) manufactured by LUBRIZOL ADVANCED MATERIALS, Inc. can be mentioned.

[0105] The composition comprises from 0.5 to 25% by weight of one or more humectants, preferably from 1 to 15% by weight, and even more preferably from 2 to 10% by weight of a polyol, relative to the total weight of the composition.

[0106] -One or more oils For the purposes of the present invention, "oil" is understood to mean a compound that is liquid at room temperature (25° C.) and that, when introduced in an amount of at least 1% by weight in water at 25° C., is either completely insoluble in water or soluble to an extent of less than 10% by weight relative to the weight of the oil introduced in the water. According to one embodiment, the oil is chosen from volatile oils, non-volatile oils and mixtures thereof. Preferably, these oils are of vegetable or vegetable origin.

[0107] The term "non-volatile oil" refers to oils that remain on the skin, scalp or oral mucosa at room temperature and atmospheric pressure for at least several hours, and are particularly suitable for use in treating -3 It means an oil having a vapor pressure of less than mmHg (0.13 Pa).

[0108] Among the non-volatile oils, cetearyl isononoate, isotridecyl isononanoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyldecyl palmitate, 2-octyldodecyl myristate or lactate, 2-diethylhexyl succinate, diisostearyl malate, triacetin, tricaprin, caprylic / capric triglyceride, mixtures of cococaprate and caprylate, benzyl alcohols of C12 to C15. zoate, butylene glycol cocoate and other glycol esters, fatty esters such as glyceryl triisostearate, tocopherol acetate and other fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid and isostearic acid, higher aliphatic alcohols such as oleyl alcohol, vegetable oils such as avocado oil, camellia oil, hazelnut oil, camellia oil, cashew nut oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia nut oil, sweet almond oil, olive oil and other mixtures thereof.

[0109] These non-volatile oils may further be of the hydrocarbon or silicone type, such as paraffin oil, squalene, petroleum jelly, dimethyl siloxane, and mixtures thereof.

[0110] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: Simmondsia chinensis Seed Oil), grape seed oil (INCI: Vitis vinifera seed oil), macadamia oil (INCI: Macadamia ternifolia seed oil), refined oleic sunflower oil (Helianthus annuus seed oil), a mixture of caprates and coco-caprylates such as the product Miglyol Coco 810 (INCI: Coco-Caprylate / Caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis Oil), sesame oil (INCI: Sesamum indicum seed oil).

[0111] By volatile oil is meant an oil that can evaporate from the skin within one hour at room temperature and atmospheric pressure. The volatile oil can be chosen, for example, from silicone oils or short chain fatty acid triglycerides to reduce the greasy feel.

[0112] According to one embodiment, the oil is present in a content ranging from 0.5 to 70% by weight, preferably from 1 to 60% by weight, preferably from 2 to 50% by weight, preferably from 5 to 40% by weight, preferably from 5 to 30% by weight, relative to the total weight of the composition.

[0113] one or more waxes and / or one or more pasty compounds. "Wax" means a fatty substance that can reversibly change between liquid and solid states, has a melting point above 25°C and generally between 30°C and 90°C, can be liquid under the conditions of preparation of the composition and has an anisotropic crystalline structure in the solid state. The waxes used according to the invention can consist of polar or apolar waxes, or a mixture of the two. "Apolar" is intended to mean waxes that contain only carbon, hydrogen and / or phosphorus atoms, in particular hydrocarbons.

[0114] The polar waxes can be selected from animal waxes, vegetable waxes, and synthetic or silicone waxes containing polar groups such as esters. Thus, mention may be made of carnauba wax, candelilla wax, beeswax (cera alba), Chinese insect wax (cephalosporum moniliforme), Japan wax, Japan wax, montan wax, triesters of C8-C20 acids and glycerin, such as glyceryl tribehenate, sold in particular under the trade name CETACENE by VEVY, acetylated glycol stearate, and mixtures thereof. These waxes can be used in particular in the form pre-dispersed in oil, as in the case of a mixture of candelilla wax and jojoba seed oil.

[0115] According to one embodiment, the waxes are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, and preferably from 5 to 10% by weight, relative to the total weight of the composition. Preferably, these waxes are of vegetable or plant origin.

[0116] "Pasty compound" is understood to mean a lipophilic fatty substance which, like wax, is capable of undergoing reversible liquid-solid state changes and which, in the solid state, has an anisotropic crystalline structure, but which differs from wax in that at a temperature of 23°C, it contains a liquid fraction and a solid fraction.

[0117] According to one embodiment, the pasty compounds are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition. These pasty compounds are preferably vegetable butters or butters of plant origin, such as shea butter or camellia butter.

[0118] According to one embodiment, the pasty compound is present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0119] -One or more gelling agents Gelling agents refer to compounds that, in the presence of a solvent, create more or less strong intrapolymer bonds and induce a three-dimensional network that immobilizes the solvent. Gelling agents also refer to thickening or rheological agents that act on the viscosity and flow properties of the aqueous or fatty phase.

[0120] The gelling agent makes it possible in particular to increase the viscosity of the continuous phase, ie to adjust the viscosity of the continuous phase to a value in the range from 100 mPa.s to 20,000 mPa.s.

[0121] The gelling agent may be selected from polymers of synthetic or vegetable origin, preferably of vegetable origin, either chemically modified or not. It may thus be selected from gums of plant origin, such as gum arabic, gum konjac, gum guar or their derivatives, gums extracted from algae, such as alginic acid, gums derived from microbial fermentation, such as xanthan, mannan, scleroglucan or their derivatives, for example the product Keltrol CG (INCI: xanthan gum) sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: xanthan gum) sold by the company JUNGBUNZLAUER INTERNATIONAL AG, starches and their derivatives, such as carboxymethylcellulose or hydroxyethylcellulose, in particular natural and modified starches, pregelatinized, acetylated, hydroxypropylated, carboxymethylated, cationic, octenylsuccinic, crosslinked starches, optionally modified several times, synthetic polymers, such as polyacrylic acid or carbomer, and mixtures thereof.

[0122] Among the starches and starch-based blends there may be mentioned Beaute by Roquette® ST 118 (INCI: Carboxymethyl starch), Beaute by Roquette® ST 720 (INCI: Hydroxypropyl starch) and Beaute by Roquette® DS112 (INCI: Starchacetate (and) Hydroxyethylcellulose (and) Xanthan gum), all sold by ROQUETTE.

[0123] Among the carbomers, mention may be made, for example, of the products Carbopol Ultrez 30 (INCI: carbomer) or CARBOPOL ETD 2050 polymer (INCI: carbomer) from LUBRIZOL ADVANCED MATERIALS, Inc.

[0124] Mention may further be made of mixtures of gum arabic and xanthan gum, such as the product Solagum AX sold by the company SEPPIC (INCI: Acacia Senegal (and) Xanthan gum), and mixtures of starch and cellulose derivatives, such as the product by Beaute by ROQUETTE (registered trademark) DS112 sold by the company ROQUETTE (INCI: Starch acetate (and) Hydroxyethylcellulose (and) Xanthan gum).

[0125] The gelling agent may be a mineral gelling agent selected from magnesium silicate and / or aluminum silicate. An example of such a mineral gelling agent is Veegum® from Vanderbilt Minerals LLC, which is a magnesium aluminum silicate.

[0126] According to one embodiment, the mineral gelling agent is present in a content ranging from 0.1 to 50% by weight, preferably from 0.5 to 25% by weight, preferably from 0.3 to 15% by weight, relative to the total weight of the composition.

[0127] - one or more binders The term "binder" refers to a compound that increases the cohesive strength of the cosmetic composition, which can be adjusted based on the amount and chemical affinity of the binder for the components of the cosmetic composition.

[0128] Typically, the binder is selected from caprylic / capric triglycerides, such as the products Labrafac CC (INCI: capric / caprylic triglycerides) or Cetyl Dimethicone (INCI).

[0129] The binder is present in the composition according to the invention in a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 5 to 12% by weight relative to the total weight of the composition.

[0130] - one or more emulsifiers Cosmetic compositions according to the present invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.

[0131] Oil-in-water (O / W) emulsifiers are those emulsifiers having an HLB of 8 or greater and selected from sorbitan esters (which may be polyethoxylated), glycerol fatty acid esters, sucrose fatty acid esters or polyesters, polyethylene glycol fatty acid esters, polyether modified polysiloxanes, polyethylene glycol fatty alcohol ethers, alkyl polyglycosides and hydrogenated lecithins, fatty alcohols, sorbitan esters (this list is not limiting), and mixtures thereof.

[0132] Examples include Montanov 68 (INCI: CETEARYL ALCOHOL (and) CETEARYL GLUCOSIDE) sold by SEPPIC, Montanov L (INCI: C14-C22 Alcohols & C12-20 Alkyl Glucoside) sold by SEPPIC, Montanov 202 (INCI: Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside) sold by CRODA, Citrol GMS 40 (INCI: Glyceryl stearate) sold by BIESTERFELD, Imwitor 960K (INCI: Glyceryl stearate) sold by BIESTERFELD, Imwitor 372P (INCI: Glyceryl stearate citrate) sold by BIESTERFELD, Glucate SS (INCI: Methyl Glucoside) sold by LUBRIZOL ADVANCED MATERIALS, Inc. These include: Polyglyceryl-6 Glucose Sesquistearate), multiple stearates (Polyglyceryl-6 Distearate), Natragem E145 (INCI: Polyglyceryl-4 Laurate / Succinate (and) Aqua) sold by CRODA, and Span 60 (INCI: sorbitan stearate) sold by SIGMA ALDRICH.

[0133] Among the sorbitan esters, mention may be made, for example, of the product Span 20.

[0134] Among fatty alcohols, mention may be made, for example, of the products sold under the name Promulgen D (INCI: Cetearyl alcohol (and) Ceteareth-20).

[0135] The W / O emulsifier may advantageously be chosen from emulsifying systems consisting of cyclodextrins and water-in-oil emulsifiers of natural origin, such as the emulsifying system sold under the name Beaute by Roquette® DS146 by Roquette Freres.

[0136] The W / O emulsifier may furthermore be chosen from emulsifying systems consisting of modified starches and gums of natural origin, such as the emulsifying system sold under the name Beaute by Roquette® DS421 by Roquette Freres.

[0137] The water-in-oil (W / O) emulsifier has an HLB of less than 8 and can be selected from non-ethoxylated polyol fatty acid esters, in particular from non-ethoxylated fatty acid esters of glycerol, polyglycerol, sorbitol, sorbitan, in particular isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrup, dextrins and anhydrohexitols such as hydrolyzed starch.

[0138] The emulsifier is present in the composition according to the invention in a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 2 to 12% by weight relative to the total weight of the composition.

[0139] - one or more surfactants According to one embodiment, the composition according to the invention comprises at least one surfactant chosen from ionic, nonionic, cationic, anionic, amphoteric or zwitterionic surfactants, these surfactants being chosen for their detergent and foaming functions.

[0140] According to another embodiment, the composition according to the invention comprises at least one surfactant chosen from anionic surfactants, amphoteric surfactants or zwitterionic surfactants.

[0141] The anionic surfactant is selected from carboxylate anionic surfactants, sulfate anionic surfactants, sulfonate surfactants, phosphate anionic surfactants, and mixtures thereof, preferably sulfonate anionic surfactants, carboxylate anionic surfactants, and mixtures thereof.

[0142] "Anionic surfactant" is intended to mean a surfactant that contains only anionic groups as ionic or ionizable groups. A substance is described herein by the term "anionic" if, under the conditions of use (e.g., medium, pH) of the composition of the invention, it does not contain a cationic charge and has at least one permanent negative charge, or if it can be ionized to give a negatively charged substance. "Sulfate-based anionic surfactants" are surfactants that contain at least one sulfate functional group (-OSO 3 H or -OSO 3 - ), optionally containing a carboxylic acid or carboxylate functional group (-COOH or -COO - ), sulfonic acid functional group (-SO 3 H or -SO 3 - ), and / or one or more other functional groups derived from an acid, such as a phosphoric acid functional group. By way of example, alkyl sulfates, alkyl ether sulfates, alkyl amido ether sulfates, alkyl aryl polyether sulfates, monoglyceride sulfates, and salts of these compounds are also sulfate anionic surfactants. The alkyl groups of these compounds mentioned by way of example contain 6 to 30 carbon atoms, and the aryl groups represent phenyl or benzyl groups. These compounds mentioned by way of example may be polyoxyalkenylated, in particular polyoxyethylenated, and contain 1 to 50 ethylene oxide units. "Non-sulfate anionic surfactants" is intended to mean surfactants that are not included in the definition of "sulfate anionic surfactants" as described above.

[0143] According to the present invention, it is also contemplated that: -Carboxylic acid anionic surfactants contain at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ), but does not contain sulfonic or sulfonic acid functional groups (-SO 3 H or -SO 3 - ) also has a sulfate functional group (-OSO 3 H or -OSO 3 - ) is also not included. -sulfonic acid anionic surfactants contain at least one sulfonic acid or sulfonate functional group (-SO 3 H or -SO 3 - ), optionally containing one or more carboxylic acids or carboxylates (-COOH or -COO - ), and / or phosphate functional groups, but may also contain sulfate functional groups (-OSO 3 H or -OSO 3 - ) cannot be included. -phosphate anionic surfactants contain at least one phosphoric acid or phosphate functional group (-OPO 3 H 2 or -OPO3 2- ), but does not contain a carboxylic acid or carboxylate functional group (-COOH or -COO - ) also contains a sulfonic acid or sulfonate functional group (-SO 3 H or -SO 3 - ) also has a sulfate functional group (-OSO 3 H or -OSO 3 - ) is also not included.

[0144] In other words: at least one sulfate functional group (-OSO 3 H or -OSO 3 - ), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ) are considered to be sulfate anionic surfactants within the meaning of the present invention and unless otherwise specified. at least one sulfate functional group (-OSO 3 H or -OSO 3 - ), and at least one sulfonic acid or sulfonate functional group (-SO 3 H or -SO 3 - ) are considered to be sulfate anionic surfactants within the meaning of the present invention and unless otherwise specified. - at least one sulfonic acid or sulfonate functional group (-SO 3 H or -SO 3 - ), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - Anionic surfactants containing at least one sulfate functional group (-OSO) are considered to be non-sulfate sulfonate anionic surfactants within the meaning of the present invention and unless otherwise indicated. 3 H or -OSO 3 - ), and at least one sulfonic acid or sulfonate functional group (-SO 3 H or -SO 3 - ), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ) are considered to be sulfate anionic surfactants within the meaning of the present invention and unless otherwise specified.

[0145] The carboxylic acid anionic surfactants may be chosen from the following compounds: acyl glycinates, acyl lactylates, acyl sarcosinates, acyl glutamates, alkyl-D-galactosiduronic acids, alkyl ether carboxylic acids, alkyl (aryl) ether carboxylic acids, alkyl (amide) ether carboxylic acids, and salts of these compounds. The alkyl and / or acyl groups of these compounds contain from 6 to 30 carbon atoms, more preferably from 8 to 28, more preferably still from 10 to 24, and even better still from 12 to 22 carbon atoms. The aryl group preferably denotes a phenyl or benzyl group. These compounds may be polyoxyalkenylated, in particular polyoxyethylenated, and then preferably contain from 1 to 50 ethylene oxide units, better still still from 2 to 10 ethylene oxide units. It is also possible to use C6-C24 alkyl monoesters and polyglycoside-polycarboxylic acids, such as C6-C24 alkyl polyglycoside citrates, C6-C24 alkyl polyglycoside tartrates, and salts thereof.

[0146] According to one embodiment, the carboxylate anionic surfactant is - C6 to C24, or even C12 to C20 acyl glutamates, such as stearoyl glutamates, in particular sodium stearoyl glutamate or disodium cocoyl glutamate, in particular sodium cocoyl glutamate or disodium cocoyl glutamate, acyl sarcosinates, in particular C6 to C24, or even C12 to C20 acyl sarcosinates, such as cocoyl sarcosinates and in particular sodium cocoyl sarcosinate, lauroyl sarcosinates and in particular sodium lauroyl sarcosinate, palmitoyl sarcosinates and in particular sodium palmitoyl sarcosinate, acyl lactylates, in particular C12 to C28, or even C14 to C24 acyl lactylates, such as behenoyl lactylates and in particular sodium behenoyl lactylate, (iso)stearoyl lactylates and in particular sodium (iso)stearoyl lactylate, - C6 to C24, in particular C12 to C20 acyl glycinates, such as cocoyl acyl glycinate, and in particular sodium cocoyl glycinate; - (C6-C30) alkyl ether carboxylic acids, in particular (C6-C24) alkyl ether carboxylic acids; - alkyl (C6-C30) aryl ether carboxylic acids, in particular alkyl (C6-C24) aryl ether carboxylic acids; - alkyl (C6-C30) amide ether carboxylic acids, in particular alkyl (C6-C24) amide ether carboxylic acids; - and mixtures thereof, in particular in the form of alkali or alkaline earth metal salts, ammonium or amino alcohols.

[0147] The sulfonic anionic surfactants may be selected from the following compounds: alkylsulfonates, alkylamidosulfonates, alkylarylsulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, α-olefinsulfonates, kerosene sulfonates, alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidosulfosuccinates, alkylsulfoacetates, N-acyltaurates, acylisethionates, alkylsulfolaurates and salts of these compounds, the alkyl groups of which contain from 6 to 30 carbon atoms, in particular from 12 to 28, even better from 14 to 24 or even from 16 to 22 carbon atoms, the aryl groups preferably denote phenyl or benzyl groups, and these compounds may be polyoxyalkenylated, in particular polyoxyethylenated, in which case they preferably contain from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.

[0148] According to one embodiment, the anionic sulfonic acid surfactant is selected from C6-C24, in particular C12-C20 alkyl sulfosuccinates, in particular lauryl sulfosuccinate, C6-C24, in particular C12-C20 alkyl ether sulfosuccinates, (C6-C24) acyl isethionates, preferably (C12-C18) acyl isethionates, α-olefin sulfonates, and mixtures thereof, in particular in the form of alkali or alkaline earth metal, ammonium or amino alcohols.

[0149] According to one embodiment, the anionic surfactant may be selected from monoesters of C6-C24 alkyl and polyglycoside-dicarboxylic acids, such as alkylglucoside citrates, alkylpolyglycoside tartrates and alkylpolyglycoside sulfosuccinates, alkylsulfosuccinamates, acyl isethionates and N-acyltaurates, the alkyl or acyl group of all these compounds preferably containing 12 to 20 carbon atoms.Another group of anionic surfactants that can be used in the compositions of the present invention is that of acyl lactylates, the acyl group of which contains 8 to 20 carbon atoms. Further examples include alkyl-D-galactosiduronic acids and their salts, as well as polyoxyalkylenated (C6-C24 alkyl) ether carboxylic acids, polyoxyalkylenated (C6-C24 alkyl) (C6-C24 aryl) ether carboxylic acids, polyoxyalkylenated (C6-C24 alkyl) amide ether carboxylic acids and their salts, especially those having 2 to 50 ethylene oxide units, and mixtures thereof.

[0150] The phosphate anionic surfactant is selected from C6-C24 alkyl phosphates, in particular C12-C20 alkyl phosphates, C6-C24 alkyl ether phosphates, in particular C12-C20 alkyl ether phosphates, and mixtures thereof.

[0151] The amphoteric or zwitterionic surfactants may be selected from secondary or tertiary or quaternary aliphatic amine derivatives, the aliphatic group being linear or branched, containing 8 to 22 carbon atoms and at least one anionic group, such as a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of alkyl (C8-C20) betaines, such as cocobetaine, sulfobetaine, alkyl (C8-C20) sulfobetaine, alkyl (C8-C20) amido alkyl (C3-C8) betaine, such as cocamidopropyl betaine, or alkyl (C8-C20) amido alkyl (C6-C8) sulfobetaine.

[0152] The cationic surfactant may be chosen from cetrimonium chloride sold under the name Microcare Quat CTC 30.

[0153] The surfactant is present in the composition according to the invention in a content ranging from 0.1% to 40%, preferably from 0.5 to 30%, preferably from 1 to 20%, preferably from 2 to 12% by weight relative to the total weight of the composition.

[0154] - one or more film formers The film-forming agent may be selected from naturally occurring polymers such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols such as polyethylene glycol, triethyl citrate, polysorbate, or even waxes such as carnauba wax or hydrogenated castor oil.

[0155] Another film former of vegetable origin is Beaute by Roquette® ST 720 hydroxypropylated pea starch sold by ROQUETTE.

[0156] The film-forming agent is present in the composition according to the invention in a content ranging from 0.1% to 20%, preferably from 0.5 to 15%, preferably from 1 to 12% by weight relative to the total weight of the composition.

[0157] One or more colorants The composition according to the invention may further comprise fillers having the effect of colouring and / or opacifying the composition and / or colouring the skin or hair or oral mucosa, such as dyes selected from at least one water-soluble or liposoluble dye, pigments, pearlescent agents, lakes (water-soluble dyes adsorbed on inert mineral carriers) and mixtures thereof. These dyes may be optionally surface-treated with hydrophobic agents such as silanes, silicones, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylates / dimethicone copolymers, C9-15 fluoroalcohol phosphate / silicon mixed copolymers, lecithin, carnauba wax, polyethylene, chitosan, and optionally amino acids that can be acylated, such as lauroyl lysine, disodium stearoyl glutamate and aluminium acyl glutamate, phytic acid. Another natural colouring agent is the caramel colouring agent by Beaute by Roquette® CC 001 sold by ROQUETTE.

[0158] "Pigment" means a white or colored mineral or organic particle intended to color and / or opacify a cosmetic composition.

[0159] Among the pigments, mention may be made of mineral or organic, natural or synthetic pigments. Examples of pigments include, in particular, oxides of iron, titanium or zinc, but also composite pigments and goniochromatic, pearlescent, interference, photochromic or thermochromic pigments, this list being non-limiting.

[0160] Among the pigments surface-treated with lecithin are UNIPURE WHITE LC981 HLC (INCI: CI 77891 (and) Hydrogenated Lecithin, UNIPURE YELLOW LC182 HLC (INCI: CI 77492 (and) Hydrogenated Lecithin), UNIPURE BLACK LC989 HLC (INCI: CI 77499 (and) Hydrogenated Lecithin, UNIPURE RED LC381 (INCI: CI 77491 (and) Hydrogenated Lecithin) from Sensient Cosmetic Technologies.

[0161] Pigments surface-treated with phytic acid include Unipure White LC 985 PHY (INCI: CI 77891 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Yellow LC 188 PHY (INCI: CI 77492 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Red LC 388 PHY (INCI: CI 77491 (and) Phytic Acid (and) Sodium Hydroxide), and Unipure Black LC 998 PHY (INCI: CI 77499 (and) Phytic Acid (and) Sodium Hydroxide) from Sensient Cosmetic Technologies.

[0162] "Pearling" is intended to mean any iridescent or non-iridescent colored particle that has a color effect due to optical interference.

[0163] Among the pearlescent agents there may be mentioned titanium mica covered with metal oxides such as iron oxide or titanium oxide.

[0164] According to one embodiment, the makeup and / or skin care composition according to the invention comprises at least colored particles, preferably pigments such as iron oxide pigments and / or pearlescent agents.

[0165] The colorant is present in the composition according to the invention in a content ranging from 0.05% to 20%, preferably from 0.1 to 15%, preferably from 0.5 to 12% by weight relative to the total weight of the composition.

[0166] -One or more sensory fillers or powders This term is intended to mean particles of any shape (especially spherical or lamellar), inorganic or organic, which are insoluble in the composition. Examples of sensory fillers or powders are talc, boron nitride, starch, such as the Beaute by Roquette® ST 005 and Beaute by Roquette® ST 012 granular starch sold by ROQUETTE, polyamides, silicone resins, silicone elastomer powders and acrylic polymer powders, especially powders of poly(methyl methacrylate) or powders of styrene acrylate copolymers (Sunsphere Powders from Dow).

[0167] The fillers are present in the composition according to the invention in a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 3 to 12% by weight relative to the total weight of the composition.

[0168] One or more sensory agents Sensate agents can be used to modify the sensory profile of a cosmetic or dermatological composition to make it more pleasant to use on the skin. The sensate agent can be selected from modified starches such as carboxymethylated starches, for example Beaute by Roquette® ST 118 from Roquette, silicas, or talc, or mixtures thereof. These sensate agents provide a soft feel for solid compositions or a cushioning effect for compositions in liquid or gel form.

[0169] The sensates are present in the composition according to the invention in a content ranging from 0.1% to 20%, preferably from 1 to 15%, preferably from 3 to 12% by weight relative to the total weight of the composition.

[0170] -One or more active ingredients In addition to the hyper-branched dextrin, the cosmetic composition may contain one or more active ingredients.

[0171] As the applicant has noted, hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, are fairly inert, have low reactivity and good compatibility with the majority of active ingredients used even in cosmetic or dermatological compositions, so that these active ingredients can be of a wide range of chemical types, which can be selected from moisturizing agents, emollients, film-forming agents, barrier agents, anti-staining agents, firming agents, anti-aging agents, antioxidants, exfoliants, collagen stimulators, anti-acne agents, sebum reducing agents, blood circulation stimulators, cooling agents, antibacterial agents, antifungal agents, anti-inflammatory agents, soothing agents, anti-irritating agents, healing agents, slimming agents, pigments, colorants, mattifying agents and fragrances.

[0172] Among analgesics, those extracted from plants are preferably used.For example, C-glycosides as disclosed in FR2902998 are used as sedatives.Natural products such as ceramides, sweet almond oil or chamomile oil, extract of Mimosa tenuiflora (tepsecohyte), aloe vera, licorice (glycyrrhetinic acid), calendula, St. John's wort, oat, linden, magnolia, marshmallow or mallow are also particularly effective sedatives.

[0173] Preferably, the hyperbranched dextrin, preferably the hyperbranched and hydrogenated dextrin, may be combined with an anti-inflammatory cosmetic active ingredient or another soothing active ingredient.

[0174] The active ingredient is present in the composition according to the invention in a content ranging from 0.05% to 20%, preferably from 0.1 to 10%, preferably from 0.5 to 6% by weight relative to the total weight of the composition. EXAMPLES

[0175] Example 1: Clinical study of discomfort induced by sodium lauryl sulfate The purpose of the study was to determine the effect of a hyperbranched and hydrogenated dextrin sold under the reference Nutriose® HM 06 by Roquette on the discomfort caused by exposure of the skin of the inner forearm of volunteers to sodium lauryl sulfate (SLS), a skin invasive product applied by patch at a concentration of 10% in water.

[0176] Volunteers and Products This non-invasive, single-center study was conducted on 40 male volunteers aged 30–55 years with sensitive skin (based on self-reporting). Volunteer inclusion criteria are shown in Table 1.

[0177] [Table 1]

[0178] The volunteers were divided into two uniform groups of 20 volunteers and each group was given a lotion according to the table below.

[0179] Lotion Composition

[0180] [Table 2]

[0181] Study Protocol At the beginning of the study (day 0), an SLS 10% patch was placed on the two delineated areas on each volunteer's forearm. The volunteers kept the patch on for 20 hours, removing the patch 4 hours before the self-assessment on day 1, and on day 1, all volunteers performed self-assessment on both forearms. Immediately after the measurements on day 1, each group applied the lotion to the area exposed to the SLS patch on the right forearm, which is the treatment area, and then performed self-assessment 5, 10 and 30 minutes after this application. The left forearm was not treated with any lotion. This is the untreated area.

[0182] Volunteers applied the same lotion to the SLS-exposed area of ​​their right forearm each night on days 1 through 6. The left forearm received no treatment. Self-evaluation of the lotion-treated and untreated areas was performed on days 2, 3, 4, and 7.

[0183] self-evaluation Volunteers rated their own sensations of discomfort, warmth and tightness in both treated and untreated areas on a semi-structured scale ranging from 1 to 10, with 1 corresponding to "not strong" and 10 corresponding to "very strong."

[0184] result

[0185] [Table 3]

[0186] The table shows the average self-evaluation of warmth sensation.

[0187] [Table 4]

[0188] The table shows the average self-evaluation of tension.

[0189] To compare the changes in sensations of warmth and tension between the different groups, the variability of these sensations was calculated, for example for treated areas of the skin, at different measurement times.

[0190] [Formula 1] For both groups, ΔTreatment((day x)-day 1)=(sensation assessed in the treatment area on day x)-(sensation assessed in the treatment area on day 1).

[0191] [Table 5]

[0192] The table describes the average change in sensation of heat and tightness over time between treated and untreated areas of skin.

[0193] Nutriose® HM 06 hyperbranched dextrin reduced SLS-induced warming sensation as early as 10 minutes compared to the placebo group, and this reduction increased and was maintained for up to 7 days.

[0194] Nutriose® HM 06 hyperbranched dextrin reduced SLS-induced tone as early as 5 minutes compared to the placebo group, and this reduction was maintained on average for up to 4 days.

[0195] The reduction in sensation of warmth and tension on the skin by application of Nutriose® HM 06 hyperbranched dextrin indicated that this dextrin could soothe the skin reaction caused by the SLS 10% patch. Thus, Nutriose® HM 06 hyperbranched and hydrogenated dextrin is soothing.

[0196] Example 2: Cosmetic formulations containing hyperbranched and hydrogenated dextrins according to the purpose of the present application Roquette's Nutriose® HM 06 hyperbranched and hydrogenated dextrin, due to its particular chemical properties previously disclosed herein, has, as the Applicant has observed, very little or no reactivity with the majority of active ingredients used in cosmetic and dermatological compositions, making it very compatible and easy to use for formulators.

[0197] Indeed, it can act as a sedative in a number of formulations, such as the following formulations, which are by way of example and not limitation:

[0198] After-sun cream

[0199] [Table 6]

[0200] Preparation protocol: Phases A and B were prepared in two separate beakers at 70°C. Phase B was then emulsified in phase A under high shear stirring for 10 minutes. This was followed by cooling to 20°C + / - 2°C. Phase C was then added under stirring, followed by phase D. Finally, the pH was adjusted to 6. A white cream was obtained with a Brookfield viscosity of 3,500 mPa.s + / - 700 (spindle No. 4, 20 rpm).

[0201] Aftershave Gel

[0202] [Table 7]

[0203] Preparation protocol: Isosorbide, Nutriose HMC 06 was premixed with the required amount of water for phase A, then Beaute by Roquette DS 112 starch was dispersed for 30-40 minutes at 80°C. Phases B1 and B2 were then added successively and the pH was adjusted to 6. A translucent gel was obtained with a Brookfield viscosity of 3,500 mPa.s + / - 700 (spindle No. 4, 20 rpm).

[0204] Soothing oil-in-water emulsion

[0205] [Table 8]

[0206] Preparation protocol: Nutriose HMC 06 was added to half the amount of water required for formulation at 45°C and stirred with a deflocculator at 500 rpm until a clear solution was obtained. Further, the ingredients of phase A2 were mixed in half the amount of water required for formulation while stirring at 500-1,000 rpm. Phase A1 was then mixed with phase A2 and phase A3 was added while stirring at 1,500 rpm for 10 minutes. Phase B was further prepared by heating to 45°C. Phase B was then emulsified in phase A1+A2+A3 while stirring vigorously at 2,000-3,000 rpm for 15 minutes at 45°C. It was cooled to 20°C + / - 2°C and phases C, D, E and F were added successively while stirring at 500 rpm and the pH was adjusted to 5.3 + / - 0.2. A blue emulsion is obtained with a Brookfield viscosity of 4,500-5,500 mPa.s (spindle No. 3, 20 rpm).

[0207] Soothing and Repairing Hand Cream

[0208] [Table 9]

[0209] Preparation protocol: Nutriose HMC 06 was added to the amount of water required for formulation at 45°C, stirred with a deflocculator at 500 rpm until a clear solution was obtained, then cooled to 20°C + / - 2°C. Next, Beaute by Roquette DS 421 was dispersed in phase A with a deflocculator at 1,000 rpm and stirred for about 10 minutes to hydrate the ingredients, which were observed visually by their opalescence. Phase C was prepared separately. At ambient temperature (20°C + / - 2°C), phase C was slowly added to phase A + phase B, stirred with a deflocculator at 2,000-3,000 rpm, then stirring was maintained for 10 minutes. Finally, phase D was added with stirring at 1,000-2,000 rpm, then adjusted to pH 4.5-4.7. A yellow cream was obtained with a Brookfield viscosity of 8,800 mPa.s (spindle 3, 20 rpm).

[0210] Calming Cleansing Cream (TO-027-001)

[0211] [Table 10]

[0212] Calming Hair Conditioning Gel (HC-040-001)

[0213] [Table 11]

[0214] Calming Hair Conditioning Cream (HC-040-002)

[0215] [Table 12]

[0216] Sedative Elixir (SC-073-003)

[0217] [Table 13]

[0218] Shampoo without sulfated surfactants (HC-031-002)

[0219] [Table 14]

[0220] Calming Shampoo (HC-025-008)

[0221] [Table 15]

[0222] After-sun cream (SC-073-011)

[0223] [Table 16]

[0224] Preparation protocol: Nutriose HM® 06 is dispersed in a mixture of water and Beaute by Roquette® PO 070 sorbitol under gentle stirring. Then Beaute by Roquette® DS 112 is added and the product is heated to 80°C under medium stirring using a deflocculating paddle and kept at this temperature for 40 minutes under stirring to obtain a homogeneous gel. It is cooled to 25-30°C under gentle stirring. Then phase B is added under medium stirring and stirring is maintained for 5 minutes. Then phase C is added under medium stirring followed by phase D under medium stirring and stirred for 5 minutes. Phase E is added under gentle stirring. Finally, the pH is adjusted to 5 using phase F.

[0225] Solar Barrier Stick (SU-024-018)

[0226] [Table 17]

[0227] Preparation protocol: Phase A ingredients are mixed under stirring and heated to 80°C. Phase B is then prepared with vigorous stirring using a deflocculating paddle (2.000 rpm) until all ingredients are well dispersed. Phase A is cooled to 60°C and then added to Phase B with gentle stirring. Holding at 60°C, the mixture is poured into molds and then cooled to 20°C. The result is a solid composition in stick form.

Claims

1. 1. Non-therapeutic use of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, as an analgesic, characterized in that said dextrin contains at least 5% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

2. The dextrin is - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42 to 50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1 to 20% 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-20% of 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

3. The dextrin is - at least 5%, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% 1-6 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-4 glycosidic bonds, which is 70% or less, preferably 60% or less, and most preferably 50% or less, based on said total of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-3 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-2 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds.

4. Non-therapeutic use according to any one of claims 1 to 3, characterized in that the soothing agent is an agent for soothing skin and / or oral mucosal reactions.

5. 1. Non-therapeutic use of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, for preventing or reducing or eliminating skin and / or oral mucosal reactions, characterized in that said dextrin contains at least 5% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

6. The dextrin is - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42 to 50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1 to 20% 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1 to 20% of 1-2 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

7. The dextrin is - at least 5%, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% 1-6 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-4 glycosidic bonds, which is 70% or less, preferably 60% or less, and most preferably 50% or less, based on said total of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-3 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-2 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds.

8. Non-therapeutic use according to any one of claims 1 to 7, characterized in that the skin reaction is a skin reaction of the skin and / or scalp and is selected from a sensation of warmth, tension, tingling, numbness, itching.

9. Non-therapeutic use according to any one of claims 1 to 7, characterized in that the oral mucosal reaction is selected from burning sensation, warmth, tension, tingling, numbness and itching.

10. Non-therapeutic use according to any one of claims 1 to 9, characterized in that the skin and / or the scalp and / or the oral mucosa are sensitive.

11. Non-therapeutic use according to any one of claims 1 to 10, characterized in that the skin and / or oral mucosal reaction is induced by endogenous and / or exogenous stress.

12. Non-therapeutic use according to any one of claims 1 to 11, characterized in that the exogenous stress is selected from chemical or pharmaceutical ingredients, mechanical insults, environmental factors, thermal insults, food and beverages.

13. Non-therapeutic use according to any one of claims 1 to 12, characterized in that the endogenous stress is selected from hormonal secretion, age, stress and sweating.

14. A method for soothing non-therapeutic care of the skin and / or scalp and / or oral mucosa, comprising the application to said skin and / or scalp and / or oral mucosa of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, characterized in that said dextrin contains at least 5% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

15. The dextrin is - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42 to 50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1 to 20% 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; 15. A non-therapeutic care method according to claim 14, characterized in that it has 1-2 glycosidic bonds in an amount of 1-2 to 20% relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

16. 16. A non-therapeutic care method according to claim 14 or claim 15, comprising the application of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, to the skin and / or scalp and / or oral mucosa exhibiting one or more skin reactions.

17. 16. A non-therapeutic care method according to claim 14 or 15, characterized in that a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, is applied to the skin and / or the scalp and / or the oral mucosa in preparation for a cosmetic or dermatological treatment or for the application of endogenous and / or exogenous stress.

18. A cosmetic composition comprising a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, in a cosmetically acceptable medium, characterized in that said dextrin contains at least 5% 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

19. The dextrin is - at least 5%, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% 1-6 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1-4 glycosidic bonds, which is 70% or less, preferably 60% or less, and most preferably 50% or less, based on said total of 1-2, 1-3, 1-4 and 1-6 bonds; - at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-3 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds; 19. The cosmetic composition according to claim 18, characterized in that it has at least 1%, preferably at least 5%, more preferably at least 10%, and most preferably at least 20% of 1-2 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds.

20. The dextrin is - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 42 to 50% 1-4 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; - 1 to 20% 1-3 glycosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds; 19. The cosmetic composition according to claim 18, characterized in that it has from 1 to 20% 1-2 glycosidic bonds relative to said sum of 1-2, 1-3, 1-4 and 1-6 bonds.

Images